RVC and Siberian researcher set up national preclinical trial center

The RVC Biofund and Siberian scientists have unveiled joint plans to set up an infrastructure company to bring preclinical trials of new drugs in Russia to global standards

The RVC Biofund, its one-year-old portfolio start-up called Viva Rus, and the Academic Institute of Cytology and Genetics in Siberia have unveiled joint plans to set up an infrastructure company to bring preclinical trials of new drugs in Russia, including those to treat cancer, to global standards, announced Russian Venture Company (RVC), the national fund of funds for innovation that established the Biofund back in 2010. ?The setup of an infrastructure company has been necessitated by a considerable increase in pharmaceutical companies and medical technology developers? demand for high-tech preclinical services. The current global requirements for the conditions in which experiments are conducted, for the lab animals used for testing, and other norms are extremely high and can hardly be met by most of Russia?s existing laboratories today,? RVC stated in its press release. The new entity is expected to operate as a contract-based research organization for preclinical trials. The project will require an estimated $1m in investment...